Eikonizo Therapeutics, Inc. was founded in October 2017 based on discoveries from Dr. Jacob Hooker’s academic lab (at MGH (Massachusetts General Hospital) and the Martinos Center for Biomedical Imaging) around novel small molecule design and human PET neuroimaging agents. ‘Eikonizo’ (ee-kuh-NEE-zo) is Greek for ‘envision’ or ‘imagine’. It captures our strategy to use PET imaging early in the drug discovery process to de-risk novel targets and lead therapeutic candidates, allowing us to envision an accelerated path to drug discovery and development. This is especially needed for brain diseases, where drug development is typically hampered by the inability to measure whether a drug has even gotten to the brain. We’re applying this approach in our lead project focusing on novel small molecule therapeutics for neurodegenerative diseases, such as Alzheimer’s Disease and ALS.
- Janice Kranz, PhD Co-Founder and CEO
- Frederick 'Al' Schroeder, PhD Co-Founder and Director of R&D
- Jacob Hooker, PhD Co-Founder
- William Shaw Co-Founder